**TBO-FILGRASTIM - BACKGROUND**

- **Generic name:** Tbo-filgrastim (Teva Biologic Organization)
- **Brand name:** Granix™
- **Manufacturer:** Teva
- **FDA approved August 29, 2012 (available December 2013)**
- **Approved via the Biologics License Application (BLA) route**
- **Not classified as a “biosimilar” because approval pathway had not yet been established at the time of submission**
- **Biosimilar Price Competition and Innovation Act signed in 2010**
- **Current indication**
- **Myelosuppressive chemotherapy recipients with non-myeloid malignancies**
- **IV formulation for tbo-filgrastim is not approved**
- **Identical to traditional filgrastim**
- **Biosimilar = “generic” biologic agent**

**TTI STUDY METHODS**

- **Mobilization methods**
  - **G-CSF 10 µg/kg (rounded to nearest vial size) daily x 4 days**
  - **If ≤10 cells/µL and 1 transplant planned, plerixafor 24 mg given**
  - **If ≤20 cells/µL and 2 transplants planned, plerixafor 24 mg given**

**TTI STUDY SUMMARY/CONCLUSION**

- **Tbo-filgrastim demonstrated similar CD34⁺ yield compared to filgrastim**
- **No difference in secondary efficacy and safety outcomes**
- **Tbo-filgrastim utilization was associated with a cost savings of approximately $1,115 per patient**

**ASBMT 2015 Abstract # 148**

For additional information, please contact Mohammed Elayan:
Email: Mohammed.Elayan@MHShealth.com

The authors have no relevant conflicts of interest to disclose.